Braveheart aims for freedom with IPO to support Hengrui-licensed cardio asset

It appears Braveheart Bio isn’t going to let Big Pharma take its freedom anytime soon, as the company is aiming for a Nasdaq listing to move its phase 3 cardiovascular drug forward.